Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia

We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Song, Yongping, Zhou, Jian, Fang, Baijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475035/
https://www.ncbi.nlm.nih.gov/pubmed/23044093
http://dx.doi.org/10.1186/1756-8722-5-61

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475035/
https://www.ncbi.nlm.nih.gov/pubmed/23044093
http://dx.doi.org/10.1186/1756-8722-5-61

Ejemplares similares